{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T05:47:47Z","timestamp":1764308867115},"reference-count":29,"publisher":"The Korean Association for the Study of the Liver","issue":"4","license":[{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["e-cmh.org"],"crossmark-restriction":true},"short-container-title":["Clin Mol Hepatol"],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:p>Background\/Aims: Data on treatment efficacy and safety of glecaprevir\/pibrentasvir (GLE\/PIB) for chronic hepatitis C virus (HCV) infection in Asian patients with severe renal impairment are limited. This study aimed to study the treatment and side effects of GLE\/PIB in these patients infected with non-1 genotype (GT) HCV.Methods: We prospectively recruited patients with Child\u2019s A cirrhosis and eGFR &lt;30 mL\/min\/1.73 m&lt;sup&gt;2&lt;\/sup&gt; in Hong Kong and Taiwan during 2017\u20132018 to receive GLE\/PIB treatment.Results: Twenty-one patients (GT2, n=7; GT3, n=6; and GT6, n=8) received GLE\/PIB for 11.2\u00b11.8 weeks. All except one were treatment-na\u00efve. GLE\/PIB was initiated in 16 patients while on dialysis (seven on peritoneal dialysis [PD] and nine on hemodialysis) and in five patients before dialysis. One patient died of PD-related peritonitis during treatment and two were lost to follow up. The SVR12 rate in the remaining 18 patients was 100%. All patients achieved undetectable levels at 4-, 12-, 24- and 48-week after treatment. Patients with deranged alanine aminotransferase showed normalization after 4 weeks and the response was sustained for 48 weeks. No significant adverse event was observed.Conclusions: GLE\/PIB treatment was associated with high efficacy and tolerability in HCV-infected patients with severe renal impairment.<\/jats:p>","DOI":"10.3350\/cmh.2020.0058","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T05:22:36Z","timestamp":1598592156000},"page":"554-561","update-policy":"http:\/\/dx.doi.org\/10.3350\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Use of glecaprevir\/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment"],"prefix":"10.3350","volume":"26","author":[{"given":"Desmond Y. H.","family":"Yap","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin S. H.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace L. H.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Sheng","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yee Tak","family":"Hui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael K. K.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yee-Man","family":"Kan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man-Fung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1902","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.01.011"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2012.01633.x"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12148"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12276"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512610"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512612"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512614"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2012.10.009"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12748"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3109\/23744235.2015.1034769"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/159795"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02558-16"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29081"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.11.011"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702417"},{"key":"ref16","first-page":"91","volume-title":"KDIGO 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease","year":"2018"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13038"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.007"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704053"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9071(199610)50:2<168::AID-JMV10>3.0.CO;2-I"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i11.2927"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30341-8"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.039"},{"key":"ref24","volume-title":"A study to evaluate the efficacy and safety of glecaprevir\/pibrentasvir (ABT-493\/ABT-530) in treatment-naive and treatment-experienced, non-cirrhotic asian adults with chronic hepatitis C virus genotype (GT) 1 to GT6 infection with or without human immunodeficiency virus co-infection (VOYAGE-1)"},{"key":"ref25","volume-title":"Efficacy and safety of glecaprevir\/pibrentasvir (ABT-493\/ABT-530) in treatment-naive and treatmentexperienced asian adults with chronic hepatitis C virus genotype (GT) 1 to GT6 infection with compensated cirrhosis and with or without human immunodeficiency virus co-infection (VOYAGE-2)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00950208"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2016.008"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1159\/000439193"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30080-2"}],"container-title":["Clinical and Molecular Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-cmh.org\/upload\/pdf\/cmh-2020-0058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-cmh.org\/journal\/view.php?doi=10.3350\/cmh.2020.0058","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-cmh.org\/upload\/pdf\/cmh-2020-0058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T06:59:44Z","timestamp":1602745184000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-cmh.org\/journal\/view.php?doi=10.3350\/cmh.2020.0058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"URL":"https:\/\/doi.org\/10.3350\/cmh.2020.0058","relation":{},"ISSN":["2287-2728","2287-285X"],"issn-type":[{"value":"2287-2728","type":"print"},{"value":"2287-285X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,1]]},"assertion":[{"value":"2020-03-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-28","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-01","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}